A Clinicopathologic Study on Chronic Alcoholic Hepatitis

This study was undertaken to evaluate the significant diagnostic points of chronic alcoholic hepatitis (CALH) among clinicopathologic findings observed. The specimens used in this study were 20 cases of CALH and 28 cases of chronic active viral hepatitis (CAVH), which were diagnosed at our University Hospital during 9 years period from 1978 to 1987. In these cases, comparative analysis of age and sex distribution, major clinical manifestations, and laboratory and histopathologic findings was performed. The results obained were summarized as follows: Among 20 cases of CALH, the sex distribution was 15 in male and 15 in female with a ratio of 3:1. The range of age distribution was wide from third to seventh decade. There was no recognizable special point about the age and sex distribution of CALH, compared with cases of CAVH. Major clinical manifestations of CALH were hepatomegaly (85%), jaundice (75%) and abdominal pain (50%). Also there was no recognizable special point about the major clinical manifestations of CALH, compared with cases of CAVH. Abnormal values of major laboratory items in CALH were observed in activities of serum r-GTP (100%), SGOT (95%), SGPT (75%) and serum alkaline phosphatase (60%), and total serum bilirubin (60%). Compared with CAVH in major laboratory findings, the significant diagnostic items of CALH were the activities of serum r-GTP and alkaline phosphatase. The characteristic histopathologic findings of CALH, which were compared with CAVH and observed in liver parenchyma, were fatty change (100%), cytoplasmic ballooning and coagulation (100%), delicate fibrosis (85%), bile stagnation (35%), and Mallory bodies (20%), and that observed blurring of limiting plate (60%) in portal and periportal areas.

Effects of Prostaglandin E_1 on Plasma Lipid Peroxides Level in Patients with Severe Chronic Active Viral Hepatitis / 第三军医大学学报

Thirty-four patients with severe chronic active viral hepatitis were divided into 2 groups. One group was treated with prostaglandin E_1, (PGE_1,) and supportive therapy, and the other was treated with supportive therapy only and served as the control. The effects of PGE_1, on plasma lipid peroxides (LPO) level, plasma prostacyclin (PGI_2) and thromboxane A_2 (TXA_2), plasma cyclic nucleotide and liver function were determined to investigate the mechanism of PGE1. It was found that PGE_1 could achieve the following effects.1. Reduction of plasma LPO level (P